MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)

Phase 2positiveQA102Positive

AI Analysis

Summary

MingMed Biotechnology announced positive Phase II clinical trial results for QA102, an oral candidate for treating intermediate age-related macular degeneration, presented at the 2026 ARVO meeting.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Positive Phase II clinical trial results for oral QA102

Importance:6/10

Sentiment:

0.75

Phase_2_DataOphthalmologyAMDClinical_TrialConference_Presentation

Related Companies

$VMAR

Read the original article

Published by PR Newswire Clinical Trials on May 6, 2026 12:28 AM

Read Original